Current management of anemia in oncology

Shelly Sharma, Sharad Sharma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anemia in oncology is the most common hematological morbidity with incidence ranging from 30-90%. Cancer-related anemia is typically multifactorial; it can be secondary to cancer itself or cancer treatment or co-existent morbidities independent of cancer. Anemia has been recognized as an independent poor prognostic factor associated with poor survival and tumor control outcomes. Treatment of anemia in an oncology setting aims at correcting any reversible underlying cause and providing supportive therapy with erythropoietin stimulating agents(ESAs) + iron therapy or PRBC transfusion. Selection of treatment option relies on individualized risk assessment of each patient. Until recently, ESAs had been the most frequent agents used but evidence of increased mortality associated with ESAs in various randomized trials has led to restriction of their use outside the chemotherapy setting. PRBC transfusion provides almost immediate correction of anemia. However, concerns regarding tumor progression and poor survival outcomes associations with transfusions have been raised following various retrospective and few prospective studies. But, in the current scenario of restricted ESA use, increased demand of this finite source in oncology is much anticipated.

Original languageEnglish (US)
Title of host publicationTransfusion Free Medicine and Surgery: Second Edition
Publisherwiley
Pages247-270
Number of pages24
ISBN (Print)9781118554685, 9780470674086
DOIs
StatePublished - Sep 22 2014

Fingerprint

Anemia
Erythropoietin
Neoplasms
Morbidity
Therapeutics
Survival
Iron
Prospective Studies
Drug Therapy
Mortality
Incidence

Keywords

  • Anemia
  • Cancer
  • Erythropoietin stimulating agents
  • Iron therapy
  • Solid tumors
  • Transfusion

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sharma, S., & Sharma, S. (2014). Current management of anemia in oncology. In Transfusion Free Medicine and Surgery: Second Edition (pp. 247-270). wiley. https://doi.org/10.1002/9781118554685.ch11

Current management of anemia in oncology. / Sharma, Shelly; Sharma, Sharad.

Transfusion Free Medicine and Surgery: Second Edition. wiley, 2014. p. 247-270.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sharma, S & Sharma, S 2014, Current management of anemia in oncology. in Transfusion Free Medicine and Surgery: Second Edition. wiley, pp. 247-270. https://doi.org/10.1002/9781118554685.ch11
Sharma S, Sharma S. Current management of anemia in oncology. In Transfusion Free Medicine and Surgery: Second Edition. wiley. 2014. p. 247-270 https://doi.org/10.1002/9781118554685.ch11
Sharma, Shelly ; Sharma, Sharad. / Current management of anemia in oncology. Transfusion Free Medicine and Surgery: Second Edition. wiley, 2014. pp. 247-270
@inbook{718ecb001f184cb7a99fae064543bdd5,
title = "Current management of anemia in oncology",
abstract = "Anemia in oncology is the most common hematological morbidity with incidence ranging from 30-90{\%}. Cancer-related anemia is typically multifactorial; it can be secondary to cancer itself or cancer treatment or co-existent morbidities independent of cancer. Anemia has been recognized as an independent poor prognostic factor associated with poor survival and tumor control outcomes. Treatment of anemia in an oncology setting aims at correcting any reversible underlying cause and providing supportive therapy with erythropoietin stimulating agents(ESAs) + iron therapy or PRBC transfusion. Selection of treatment option relies on individualized risk assessment of each patient. Until recently, ESAs had been the most frequent agents used but evidence of increased mortality associated with ESAs in various randomized trials has led to restriction of their use outside the chemotherapy setting. PRBC transfusion provides almost immediate correction of anemia. However, concerns regarding tumor progression and poor survival outcomes associations with transfusions have been raised following various retrospective and few prospective studies. But, in the current scenario of restricted ESA use, increased demand of this finite source in oncology is much anticipated.",
keywords = "Anemia, Cancer, Erythropoietin stimulating agents, Iron therapy, Solid tumors, Transfusion",
author = "Shelly Sharma and Sharad Sharma",
year = "2014",
month = "9",
day = "22",
doi = "10.1002/9781118554685.ch11",
language = "English (US)",
isbn = "9781118554685",
pages = "247--270",
booktitle = "Transfusion Free Medicine and Surgery: Second Edition",
publisher = "wiley",

}

TY - CHAP

T1 - Current management of anemia in oncology

AU - Sharma, Shelly

AU - Sharma, Sharad

PY - 2014/9/22

Y1 - 2014/9/22

N2 - Anemia in oncology is the most common hematological morbidity with incidence ranging from 30-90%. Cancer-related anemia is typically multifactorial; it can be secondary to cancer itself or cancer treatment or co-existent morbidities independent of cancer. Anemia has been recognized as an independent poor prognostic factor associated with poor survival and tumor control outcomes. Treatment of anemia in an oncology setting aims at correcting any reversible underlying cause and providing supportive therapy with erythropoietin stimulating agents(ESAs) + iron therapy or PRBC transfusion. Selection of treatment option relies on individualized risk assessment of each patient. Until recently, ESAs had been the most frequent agents used but evidence of increased mortality associated with ESAs in various randomized trials has led to restriction of their use outside the chemotherapy setting. PRBC transfusion provides almost immediate correction of anemia. However, concerns regarding tumor progression and poor survival outcomes associations with transfusions have been raised following various retrospective and few prospective studies. But, in the current scenario of restricted ESA use, increased demand of this finite source in oncology is much anticipated.

AB - Anemia in oncology is the most common hematological morbidity with incidence ranging from 30-90%. Cancer-related anemia is typically multifactorial; it can be secondary to cancer itself or cancer treatment or co-existent morbidities independent of cancer. Anemia has been recognized as an independent poor prognostic factor associated with poor survival and tumor control outcomes. Treatment of anemia in an oncology setting aims at correcting any reversible underlying cause and providing supportive therapy with erythropoietin stimulating agents(ESAs) + iron therapy or PRBC transfusion. Selection of treatment option relies on individualized risk assessment of each patient. Until recently, ESAs had been the most frequent agents used but evidence of increased mortality associated with ESAs in various randomized trials has led to restriction of their use outside the chemotherapy setting. PRBC transfusion provides almost immediate correction of anemia. However, concerns regarding tumor progression and poor survival outcomes associations with transfusions have been raised following various retrospective and few prospective studies. But, in the current scenario of restricted ESA use, increased demand of this finite source in oncology is much anticipated.

KW - Anemia

KW - Cancer

KW - Erythropoietin stimulating agents

KW - Iron therapy

KW - Solid tumors

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=84948761911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948761911&partnerID=8YFLogxK

U2 - 10.1002/9781118554685.ch11

DO - 10.1002/9781118554685.ch11

M3 - Chapter

SN - 9781118554685

SN - 9780470674086

SP - 247

EP - 270

BT - Transfusion Free Medicine and Surgery: Second Edition

PB - wiley

ER -